Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.34 |
| ▸ | NQO2 | P16083 | 6/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6608288 | 0.92 | CXCR4 (0.37) | CREBBPSMYD3CXCR4 | |
| SCHEMBL6612191 | 0.91 | CXCR4 (0.37) | CREBBPSMYD3CXCR4 | |
| SCHEMBL5188359 | 0.88 | TMEM97 (0.32) | SMYD3 | |
| SCHEMBL5189243 | 0.88 | TMEM97 (0.32) | SMYD3 | |
| SCHEMBL6281965 | 0.88 | TMEM97 (0.32) | SMYD3 | |
| SCHEMBL5188625 | 0.88 | TMEM97 (0.32) | SMYD3 | |
| SCHEMBL6302745 | 0.86 | TMEM97 (0.31) | SMYD3 | |
| SCHEMBL6302937 | 0.85 | TMEM97 (0.31) | — | |
| SCHEMBL6613807 | 0.84 | CXCR4 (0.37) | CXCR4 | |
| SCHEMBL5473257 | 0.83 | CA14 (0.40) | CA14MTNR1AMTNR1BNQO2CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049583-A1 | Benzoxazine and benzothiazine derivatives and their use in pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-03-01 | — | — | US | disclosed |
| US-7141566-B1 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049583-A1 | Benzoxazine and benzothiazine derivatives and their use in pharmaceutical agents | CYP3A5, XDH, CYP4Z1 | CA14 2410/4885MTNR1A 1044/4885MTNR1B 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.